BioCentury | Mar 7, 2020
Product Development

If NoNO’s stroke trial strategy pays off, it could bring the first new therapy in a generation

...is also possible,” he said. At least one other company is targeting PSD95 for stroke. Avilex Pharma ApS...
BioCentury | Apr 29, 2013
Emerging Company Profile

Avilex: One-two pain punch

...with severe cognitive and motor side effects. Rather than go after the NMDA receptor directly, Avilex...
...PDS95 has been identified as an interesting target for 10-15 years, the unique part of Avilex's...
...for PSD95 and a substantially longer half-life in human serum in vitro than NoNo's compound. Avilex's...
BioCentury | Apr 22, 2013
Financial News

Avilex completes venture financing

Avilex Pharma ApS , Denmark Business: Neurology Date completed: 4/15/13 Type: Venture financing Raised: Not disclosed Investor: Novo Seeds WIR Staff Neurology...
BioCentury | Apr 17, 2013
Financial News

Avilex debuts to develop compounds for neuropathic pain

...molecule ligands targeting discs large homolog 4 ( DLG4 ; PSD95 ) for neurology indications. Avilex's...
...optimization phase, with preclinical development for one or both molecules slated to start next half. Avilex...
Items per page:
1 - 4 of 4
BioCentury | Mar 7, 2020
Product Development

If NoNO’s stroke trial strategy pays off, it could bring the first new therapy in a generation

...is also possible,” he said. At least one other company is targeting PSD95 for stroke. Avilex Pharma ApS...
BioCentury | Apr 29, 2013
Emerging Company Profile

Avilex: One-two pain punch

...with severe cognitive and motor side effects. Rather than go after the NMDA receptor directly, Avilex...
...PDS95 has been identified as an interesting target for 10-15 years, the unique part of Avilex's...
...for PSD95 and a substantially longer half-life in human serum in vitro than NoNo's compound. Avilex's...
BioCentury | Apr 22, 2013
Financial News

Avilex completes venture financing

Avilex Pharma ApS , Denmark Business: Neurology Date completed: 4/15/13 Type: Venture financing Raised: Not disclosed Investor: Novo Seeds WIR Staff Neurology...
BioCentury | Apr 17, 2013
Financial News

Avilex debuts to develop compounds for neuropathic pain

...molecule ligands targeting discs large homolog 4 ( DLG4 ; PSD95 ) for neurology indications. Avilex's...
...optimization phase, with preclinical development for one or both molecules slated to start next half. Avilex...
Items per page:
1 - 4 of 4